{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:30:56Z","timestamp":1776295856757,"version":"3.50.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer efficacy of a treatment and the devastating heart complications it could potentially cause. Oncocardiology has emerged as a promising medical and scientific field addressing these aspects from different angles. Interestingly, nanomedicine appears to have great promise in reducing the cardiotoxicity of anticancer drugs, maintaining or even enhancing their efficacy. Several studies have shown the benefits of nanocarriers, although with some flaws when considering the concept of oncocardiology. Herein, we discuss how preclinical studies should be designed as closely as possible to clinical protocols, considering various parameters intrinsic to the animal models used and the experimental protocols. The sex and age of the animals, the size and location of the tumors, the doses of the nanoformulations administered, and the acute vs. the long-term effects of treatments are essential aspects. We also discuss the perspectives offered by non-invasive imaging techniques to simultaneously assess both the anticancer effects of treatment and its potential impact on the heart. The overall objective is to accelerate the development and validation of nanoformulations through high-quality preclinical studies reproducing the clinical conditions.<\/jats:p>","DOI":"10.3389\/fcvm.2021.690533","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T04:38:58Z","timestamp":1625027938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies"],"prefix":"10.3389","volume":"8","author":[{"given":"Gabriel Silva Marques","family":"Borges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Burgarelli","family":"Lages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sicard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Ant\u00f4nio Miranda","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ijcard.2016.09.046","article-title":"Management and research in cancer treatment-related cardiovascular toxicity: challenges and perspectives","volume":"224","author":"Cautela","year":"2016","journal-title":"Int J Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2017.06.001","article-title":"Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention","volume":"263","author":"Masoudkabir","year":"2017","journal-title":"Atherosclerosis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cvr\/cvz048","article-title":"Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need","volume":"115","author":"Moslehi","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10147-019-01426-w","article-title":"Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study","volume":"24","author":"Okura","year":"2019","journal-title":"Int J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology","volume":"118","author":"Lenneman Carrie","year":"2016","journal-title":"Circ Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/CIRCRESAHA.116.309573","article-title":"The future of onco-cardiology: we are not just \u201cSide Effect Hunters","volume":"119","author":"Abe","year":"2016"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1161\/CIRCULATIONAHA.114.010486","article-title":"Myocardial protection during cardiotoxic chemotherapy","volume":"132","author":"Witteles","year":"2015","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2016.2132","article-title":"Oncocardiology-past, present, and future: a review","volume":"1","author":"Yeh","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/14740338.2018.1513489","article-title":"Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2","volume":"17","author":"Manolis","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00885-3.","article-title":"Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities","author":"Monahan","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J Control Release."},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin Transl Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.colsurfb.2016.05.070","article-title":"Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(\u03b5-caprolactone) copolymer micelle for combination cancer chemotherapy","volume":"145","author":"Yan","year":"2016","journal-title":"Colloids Surf B Biointerfaces."},{"key":"B18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs."},{"key":"B19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2147\/IJN.S149887","article-title":"Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity","volume":"13","author":"Dou","year":"2018","journal-title":"Int J Nanomedicine."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110876","DOI":"10.1016\/j.biopha.2020.110876","article-title":"Co-delivery of doxorubicin, docosahexaenoic acid, and \u03b1-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity","volume":"132","author":"Lages","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/critrevtherdrugcarriersyst.v12.i1.10","article-title":"Biodegradable microspheres in drug delivery","volume":"12","author":"Okada","year":"1995","journal-title":"Crit Rev Ther Drug Carrier Syst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.nano.2009.02.002","article-title":"PEGylated PLGA nanoparticles for the improved delivery of doxorubicin","volume":"5","author":"Park","year":"2009","journal-title":"Nanomedicine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0133569","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","article-title":"Nanomaterials for T-cell cancer immunotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Nat Nanotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12060","DOI":"10.1038\/s41598-020-68907-1","article-title":"Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4","volume":"10","author":"Golforoush","year":"2020","journal-title":"Sci Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11886-020-01325-x","article-title":"Pluripotent stem cell modeling of anticancer therapy-induced cardiotoxicity","volume":"22","author":"Lyra-Leite","year":"2020","journal-title":"Curr Cardiol Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fcvm.2020.00050","article-title":"Human pluripotent stem cell-derived cardiomyocytes for assessment of anticancer drug-induced cardiotoxicity","volume":"7","author":"Schwach","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3892\/ijo_00000547","article-title":"Chronologic aging decreases tumor angiogenesis and metastasis in a mouse model of head and neck cancer","volume":"36","author":"Bojovic","year":"2010","journal-title":"Int J Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2017.02.018","article-title":"Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: comparing single and combined therapy in young and old mice","volume":"257","author":"Andriyanov","year":"2017","journal-title":"J Control Release."},{"key":"B33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tcm.2009.12.004","article-title":"Cardiac aging in mice and humans: the role of mitochondrial oxidative stress","volume":"19","author":"Dai","year":"2009","journal-title":"Trends Cardiovasc Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"a025148","DOI":"10.1101\/cshperspect.a025148","article-title":"The aging heart","volume":"5","author":"Chiao","year":"2015","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13293-020-00291-x","article-title":"Sex differences in cancer mechanisms","volume":"11","author":"Rubin","year":"2020","journal-title":"Biol Sex Differ."},{"key":"B36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","article-title":"Gender differences in coronary heart disease","volume":"18","author":"Maas","year":"2010","journal-title":"Neth Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10741-019-09820-2","article-title":"Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens","volume":"24","author":"Cadeddu Dessalvi","year":"2019","journal-title":"Heart Fail Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jso.25150","article-title":"Advantages of patient-derived orthotopic mouse models and genetic reporters for developing fluorescence-guided surgery","volume":"118","author":"Lwin","year":"2018","journal-title":"J Surg Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J Control Release."},{"key":"B40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anticancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv Drug Deliv Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1177\/1078155218798157","article-title":"Renal toxicity with liposomal doxorubicin in metastatic breast cancer","volume":"25","author":"Yemm","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00280-020-04203-z","article-title":"Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review","volume":"87","author":"Savani","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcvm.2018.00009","article-title":"Cardiotoxicity of anticancer therapeutics","volume":"5","author":"Dong","year":"2018","journal-title":"Front Cardiovasc Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MPH.0000000000001112","article-title":"Aerobic exercise during early murine doxorubicin exposure mitigates cardiac toxicity","volume":"40","author":"Wang","year":"2018","journal-title":"J Pediatr Hematol Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nbt0906-1065b","article-title":"The dog as a cancer model","volume":"24","author":"Khanna","year":"2006","journal-title":"Nat Biotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1038\/s41388-019-0776-8","article-title":"Non-murine models to investigate tumor-immune interactions in head and neck cancer","volume":"38","author":"Rossa","year":"2019","journal-title":"Oncogene."},{"key":"B48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","article-title":"Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes","volume":"7","author":"Gianni","year":"2007","journal-title":"Cardiovasc Toxicol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12574-018-0394-4","article-title":"Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy","volume":"17","author":"El-Sherbeny","year":"2019","journal-title":"J Echocardiogr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1089\/hum.2018.036","article-title":"Heparan sulfate binding coxsackievirus B3 strain PD: a novel avirulent oncolytic agent against human colorectal carcinoma","volume":"29","author":"Hazini","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"109323","DOI":"10.1016\/j.biopha.2019.109323","article-title":"Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model","volume":"118","author":"de Oliveira Silva","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1055\/s-0035-1569447","article-title":"The comparison of biodistribution, efficacy and toxicity of two PEGylated liposomal doxorubicin formulations in mice bearing c-26 colon carcinoma: a preclinical study","volume":"66","author":"Razavi-Azarkhiavi","year":"2016","journal-title":"Drug Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2013.01.009","article-title":"cRGD-functionalized polymeric magnetic nanoparticles as a dual-drug delivery system for safe targeted cancer therapy","volume":"70","author":"Shen","year":"2013","journal-title":"Pharmacol Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.acvd.2019.07.001","article-title":"Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer","volume":"112","author":"Thuny","year":"2019","journal-title":"Arch Cardiovasc Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e013755","DOI":"10.1161\/JAHA.119.013755","article-title":"Multimodality cardiac imaging in the era of emerging cancer therapies","volume":"9","author":"Biersmith","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12265-020-10028-1","article-title":"Cardiac imaging in oncology patients in Europe: a model for advancement of CV safety and development of comprehensive CV care","volume":"13","author":"L\u00f3pez-Fern\u00e1ndez","year":"2020","journal-title":"J Cardiovasc Transl Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1113\/expphysiol.2012.068577","article-title":"High-resolution echocardiography in the assessment of cardiac physiology and disease in preclinical models","volume":"98","author":"Moran","year":"2013","journal-title":"Exp Physiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"44998","DOI":"10.1038\/srep44998","article-title":"Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti-trypanosomal lychnopholide","volume":"7","author":"Branquinho","year":"2017","journal-title":"Sci Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"H684","DOI":"10.1152\/ajpheart.00573.2018","article-title":"Right coronary artery ligation in mice: a novel method to investigate right ventricular dysfunction and biventricular interaction","volume":"316","author":"Sicard","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1111\/bph.15186","article-title":"Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation","volume":"177","author":"Moreira Souza","year":"2020","journal-title":"Br J Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"13803","DOI":"10.18632\/oncotarget.3144","article-title":"Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer","volume":"6","author":"Ader","year":"2015","journal-title":"Oncotarget."},{"key":"B63","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.canlet.2018.06.023","article-title":"Targeting the NRG1\/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer","volume":"432","author":"Ogier","year":"2018","journal-title":"Cancer Lett."},{"key":"B64","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1158\/0008-5472.CAN-05-0440","article-title":"Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models","volume":"65","author":"Graham","year":"2005","journal-title":"Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1038\/s41598-019-46410-6","article-title":"Development of orthotopic tumour models using ultrasound-guided intrahepatic injection","volume":"9","author":"McVeigh","year":"2019","journal-title":"Sci Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/php.13016","article-title":"Size-dependent tumor response to photodynamic therapy and irinotecan monotherapies revealed by longitudinal ultrasound monitoring in an orthotopic pancreatic cancer model","volume":"95","author":"Pigula","year":"2019","journal-title":"Photochem Photobiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0153532","DOI":"10.1371\/journal.pone.0153532","article-title":"High resolution ultrasound and photoacoustic imaging of orthotopic lung cancer in mice: new perspectives for onco-pharmacology","volume":"11","author":"Raes","year":"2016","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s42492-020-00061-x","article-title":"Recent advances in applications of multimodal ultrasound-guided photoacoustic imaging technology","volume":"3","author":"Wang","year":"2020","journal-title":"Vis Comput Ind Biomed Art."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.ultrasmedbio.2018.05.021","article-title":"Real-time in vivo photoacoustic imaging in the assessment of myocardial dynamics in murine model of myocardial ischemia","volume":"44","author":"Mukaddim","year":"2018","journal-title":"Ultrasound Med Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pacs.2019.03.001","article-title":"Cardiovascular optoacoustics: from mice to men - a review","volume":"14","author":"Karlas","year":"2019","journal-title":"Photoacoustics."},{"key":"B71","doi-asserted-by":"publisher","first-page":"615507","DOI":"10.3389\/fcvm.2020.615507","article-title":"Experimental myocardial infarction elicits time-dependent patterns of vascular hypoxia in peripheral organs and in the brain","volume":"7","author":"David","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nmeth.3929","article-title":"Contrast agents for molecular photoacoustic imaging","volume":"13","author":"Weber","year":"2016","journal-title":"Nat Methods."},{"key":"B73","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2967\/jnumed.120.245241","article-title":"Photoacoustic molecular imaging for the identification of lymph node metastasis in head and neck cancer using an anti-EGFR antibody-dye conjugate","volume":"62","author":"Nishio","year":"2020","journal-title":"J Nucl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.690533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T04:39:01Z","timestamp":1625027941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.690533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":75,"alternative-id":["10.3389\/fcvm.2021.690533"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.690533","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"article-number":"690533"}}